2022 KU Post San Antonio Review | Early-Stage Hormone + Breast Cancer: Optimizing Systemic Therapy

2022 KU Post San Antonio Review | (Neo)adjuvant Therapy for Triple Negative Breast CancerПодробнее

Adjuvant Treatment for Early Stage Hormone Positive Breast Cancer: Role of Genomic SignaturesПодробнее

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment ApproachesПодробнее

2022 KU Post San Antonio Review | Breast Cancer Risk Assessment and Reduction: What's NewПодробнее

2022 KU Post San Antonio Review | Monday Morning Practice Implications: Q&A and Case Discussion 1Подробнее

2022 KU Post San Antonio Review | Monday Morning Practice Implications: Q&A and Case Discussion 2Подробнее

Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast CancerПодробнее

The San Antonio Breast Cancer Symposium (SABCS) 2022Подробнее

San Antonio Breast Cancer Symposium 2022 highlightsПодробнее

Exploring Neoadjuvant Therapy for Breast Cancer: What You Need to KnowПодробнее

ASCO Early-Stage Breast Cancer Updates | Allison Zibelli, MD | Sidney Kimmel Cancer CenterПодробнее

Dr. Shom Goel |San Antonio Breast Cancer Symposium 2022 | Year in ReviewПодробнее

First-line camizestrant for ER+/HER2- advanced breast cancerПодробнее

Key Takeaways | 2022 West Oncology ConferenceПодробнее

2022 West Oncology Conference | Breast Cancers | Early-StageПодробнее

Dr. Marleen Kok | San Antonio Breast Cancer Symposium 2022 | Year in ReviewПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Bagegni & Dr. GradisharПодробнее

First-in-human results of CDK2/4/6 inhibition in breast and ovarian cancerПодробнее